Genmab FRα ADC Cuts Death Risk 57% in Global Late-Stage Ovarian Cancer Trial
Start here
Genmab's folate receptor alpha-targeting antibody-drug conjugate has met its goal in a global late-stage ovarian cancer trial, reducing the risk of death by 57% in the intention-to-treat population. In the primary analysis set population, the risk of death fell by 56%. Investors reacted strongly: Genmab's share price rose 9.5% on the day of the announcement, lifting its market capitalization to $27.3 billion. Still open are the full trial details, such as complete efficacy and safety data, regulatory filing plans, and the commercial timeline for the drug.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickGenmab FRα ADC Succeeds in Global Late-Stage Ovarian Cancer Trial, Cutting Death Risk 57% in ITT Population
Genmab's FRα ADC succeeded in a global late-stage ovarian cancer trial, reducing the risk of death by 57% in the ITT population. In the PAS population, the risk of death fell by 56%. Genmab's share price rose 9.5% on the day, bringing its market cap to $27.3 billion.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 24 13:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.